Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
In Indonesia, especially among the Javanese, the jamu traditional herbal medicine may have originated in the Mataram kingdom era, some 1300 years ago. The bas-reliefs on Borobudur depict the image of people grinding herbs with stone mortar and pestle, a drink seller, a herbalist, and masseuse treating people. The Madhawapura inscription from Majapahit period mentioned a specific profession of herb mixer and combiner (herbalist), called Acaraki. The book from Mataram dated from circa 1700 contains 3,000 entries of jamu herbal recipes, while Javanese classical literature Serat Centhini (1814) describes some jamu herbal concoction recipes. Though possibly influenced by Indian Ayurveda systems, the Indonesia archipelago holds numerous indigenous plants not found in India, including plants similar to those in Australia beyond the Wallace Line. Jamu practices may vary from region to region, and are often not recorded, especially in remote areas of the country. Although primarily herbal, some Jamu materials are acquired from animals, such as honey, royal jelly, milk, and Ayam Kampung eggs.
=== Hotels === The Regent Palace Hotel, Glasshouse Street, London was operated by Strand Hotels Limited, a subsidiary of J. Lyons and Company and opened on 16 May 1915. Strand Hotels also operated the Cumberland Hotel (Marble Arch, London), Kingsley Hotel, Park Court Hotel, Windsor Hotel, White's Hotel and the Strand Palace Hotel after the inception of Strand Hotels Limited. The last London hotel that they operated until the demise of the group in the mid-1970s was the Tower Hotel situated by Tower Bridge in London.
In addition to drug crops, it is also not uncommon for drug farms to also host livestock, both to have a legal source of revenue to help disguise the dirty money and so that the livestock can provide a source of organic fertilizer (such as manure) for the drug crops. There are multiple instances where traffickers set up some of their drug farms, safe houses and drug labs in remote wilderness areas. Once produced, the fully processed narcotics are then transported to more populated areas to be sold. Oftentimes the traffickers stationed in these remote criminal settlements, sustain themselves with a combination of survival skills and with food, supplies and workers being brought to them by associates. The reason that traffickers have been known to establish such remote compounds is so that the surrounding area can help to provide varying degrees of natural cover. Additionally the traffickers may also hope, that the surrounding terrain and local wildlife might serve to deter or impede either investigative authorities or rival gangs if the location of the clandestine compound were revealed. While usually thought of as an urban issue, drug trafficking is also known to be a problem in both suburban and rural areas as well.
United States v. GlaxoSmithKline was a case before the United States District Court for the Eastern District of Pennsylvania. Robert J. Merena was one of the first who filed claims against SmithKline Beecham Clinical Laboratories on November 12, 1993. The complaints alleged that GlaxoSmithKline, which operated a system of clinical laboratories, adopted myriad complicated procedures for the purpose of defrauding state and federal healthcare programs, in particular Medicare and Medicaid. The U.S. Justice Department publicly praised Robert Merena for his "cooperation and support" in helping the government collect the largest settlement ever involving a whistle-blower lawsuit. The SmithKline settlement is considered to be one of the largest whistleblower assisted recoveries in the history of the United States.
Sources: en.wikipedia.org
== History == Loperamide hydrochloride was first synthesized in 1969 by Paul Janssen from Janssen Pharmaceuticals in Beerse, Belgium, following previous discoveries of diphenoxylate hydrochloride (1956) and fentanyl citrate (1960). The first clinical reports on loperamide were published in 1973 with the inventor being one of the authors. The trial name for it was "R-18553". Loperamide oxide has a different research code: R-58425. The trial against placebo was conducted from December 1972 to February 1974, its results being published in 1977. In 1973, Janssen started to promote loperamide under the brand name Imodium. In December 1976, Imodium got US FDA approval. During the 1980s, Imodium became the best-selling prescription antidiarrheal in the United States. In March 1988, McNeil Pharmaceutical began selling loperamide as an over-the-counter drug under the brand name Imodium A-D. In the 1980s, loperamide also existed in the form of drops (Imodium Drops) and syrup. Initially, it was intended for children's usage, but Johnson & Johnson voluntarily withdrew it from the market in 1990 after 18 cases of paralytic ileus (resulting in six deaths) were registered in Pakistan and reported by the World Health Organization (WHO). In the following years (1990-1991), products containing loperamide have been restricted for children's use in several countries (ranging from two to five years of age). In the 1980s, before the US patent expired on 30 January 1990, McNeil started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas.
The music of Brazil was formed mainly from the fusion of European, Native Indigenous, and African elements. Until the nineteenth century, Portugal was the gateway to most of the influences that built Brazilian music, although many of these elements were not of Portuguese origin, but generally European. The first was José Maurício Nunes Garcia, author of sacred pieces with an influence of Viennese classicism. The major contribution of the African element was the rhythmic diversity and some dances and instruments. Popular music since the late eighteenth century, samba was considered the most typical and on the UNESCO cultural heritage list. Samba-reggae, Axé, Maracatu, Frevo and Afoxê are four music traditions that have been popularized by their appearance in the annual Brazilian Carnivals. Capoeira is usually played with its own music referred to as capoeira music, which is usually considered to be a call-and-response type of folk music. Forró is a type of folk music prominent during the Festa Junina in northeastern Brazil. Jack A. Draper III, a professor of Portuguese at the University of Missouri, argues that Forró was used as a way to subdue feelings of nostalgia for a rural lifestyle. Choro is a popular musical instrumental style. Its origins are in 19th-century Rio de Janeiro. The style often has a fast and happy rhythm, characterized by subtle modulations and full of syncopation and counterpoint. lambada and Carimbó achieved success in Latin music, originating from Pará.
Orlistat is a lipase inhibitor which prevents the absorption of fats after meals. It is approved in children 12 years and older, but use is often limited due to adverse reactions of bowel urgency, fecal incontinence, flatulence and it may cause deficiencies in fat-soluble vitamins. Phentermine is an amphetamine analogue which is used as an appetite suppressant; it may be used for up to 12 weeks at a time in adolescents 16 years and older. Possible adverse reactions include headache, nausea, palpitations, elevations in blood pressure, restlessness or insomnia. Phentermine is also available in combination with topiramate extended release and the combination is approved for use in adolescents 12 years and older. Topiramate is an anticonvulsant, but has been shown to cause weight loss. Phentermine-topiramate XR has similar possible side effects to phentermine and users should be on contraception due to the risk of teratogenic effects of the medication. Liraglutide and semaglutide are glucagon-like peptide-1 receptor agonists which are approved for the treatment of obesity in adolescents 12 years and older. Liraglutide is a once-daily injection and semaglutide is a once-weekly injection. They are thought to work by delaying gastric emptying, decreasing appetite and increasing satiety. Possible side effects of liraglutide or semaglutide include gastrointestinal distress including nausea, vomiting, diarrhea or constipation, abdominal discomfort or indigestion.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.